AstraZeneca's cancer drug combo hits main survival goal in late-stage trial

AZN•2026-09-08

Imfinzi and Imdelltra improve overall survival

AstraZeneca said on Tuesday its cancer drug Imfinzi combined with Amgen's targeted immunotherapy Imdelltra significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial.

AstraZeneca's cancer drug combo hits main survival goal in late-stage trial

Imfinzi and Imdelltra improve overall survival

Related News

Scinai ends PC111 licensing deal, shifts R&D focus to NanoAb platform

Amex Halt <SMRX.A> Add Info Lst 25.336100

General Dynamics Corp <GD.N>: UBS raises target price to $408 from $395

Xerox investor urges review of financial services unit, Bloomberg News reports

HF Sinclair Corporation <DINO.N>: UBS Raises Target Price to $126 From $105